CMS creates permanent drug code for treating molluscum contagiosum

CMS has created a permanent drug code, J7354, for cantharidin, a drug used to treat molluscum contagiosum in adult and pediatric patients 2 years and older. The new J-code became effective on April 1, 2024.

Cantharidin is the first FDA-approved topical treatment for molluscum contagiosum. The manufacturer provides the topical biologic in a single-use sealed glass ampule containing 3.2 mg of 0.7% cantharidin solution.

Treatment of molluscum contagiosum using cantharidin can be reported with the appropriate evaluation and management (E/M) code when performed, and clinical staff in the practice can apply the medication as part of the dermatologist’s treatment plan.

When billing for cantharidin using J7354, the claim form should indicate the drug’s name, strength, NCD number from the manufacturer’s pamphlet, and dosage. Pricing information will be available on the CMS website at Medicare HCPCS Quarterly Updates.